AU2605097A - Cyclic peptide vaccines for treatment and prevention of diabetes - Google Patents
Cyclic peptide vaccines for treatment and prevention of diabetesInfo
- Publication number
- AU2605097A AU2605097A AU26050/97A AU2605097A AU2605097A AU 2605097 A AU2605097 A AU 2605097A AU 26050/97 A AU26050/97 A AU 26050/97A AU 2605097 A AU2605097 A AU 2605097A AU 2605097 A AU2605097 A AU 2605097A
- Authority
- AU
- Australia
- Prior art keywords
- peptide
- peptides
- mhc polypeptide
- amino acid
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010069514 Cyclic Peptides Proteins 0.000 title description 20
- 102000001189 Cyclic Peptides Human genes 0.000 title description 20
- 238000011282 treatment Methods 0.000 title description 15
- 206010012601 diabetes mellitus Diseases 0.000 title description 10
- 230000002265 prevention Effects 0.000 title description 4
- 229940023041 peptide vaccine Drugs 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 246
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 134
- 229920001184 polypeptide Polymers 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 59
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 230000002163 immunogen Effects 0.000 claims description 33
- 230000028993 immune response Effects 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 229940037003 alum Drugs 0.000 claims description 17
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 17
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims description 16
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 15
- 125000004122 cyclic group Chemical group 0.000 claims description 12
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 31
- 150000001413 amino acids Chemical group 0.000 description 29
- 239000011347 resin Substances 0.000 description 23
- 229920005989 resin Polymers 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 238000007363 ring formation reaction Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 108700028369 Alleles Proteins 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000010511 deprotection reaction Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 108090000288 Glycoproteins Proteins 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000010647 peptide synthesis reaction Methods 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 230000002939 deleterious effect Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- FDJABJJEKWDNQO-UHFFFAOYSA-N pentane;propan-2-one Chemical compound CC(C)=O.CCCCC FDJABJJEKWDNQO-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 210000000628 antibody-producing cell Anatomy 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 150000003568 thioethers Chemical class 0.000 description 4
- -1 β-γ-δ-amino acids Chemical class 0.000 description 4
- QASBCTGZKABPKX-UHFFFAOYSA-N 4-(methylsulfanyl)phenol Chemical compound CSC1=CC=C(O)C=C1 QASBCTGZKABPKX-UHFFFAOYSA-N 0.000 description 3
- NIFAOMSJMGEFTQ-UHFFFAOYSA-N 4-methoxybenzenethiol Chemical compound COC1=CC=C(S)C=C1 NIFAOMSJMGEFTQ-UHFFFAOYSA-N 0.000 description 3
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 3
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000006472 autoimmune response Effects 0.000 description 3
- 238000006664 bond formation reaction Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000007030 peptide scission Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FHOAKXBXYSJBGX-YFKPBYRVSA-N (2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)C(O)=O FHOAKXBXYSJBGX-YFKPBYRVSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 150000007649 L alpha amino acids Chemical class 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000022602 disease susceptibility Diseases 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- FUKOTTQGWQVMQB-UHFFFAOYSA-N (2-bromoacetyl) 2-bromoacetate Chemical compound BrCC(=O)OC(=O)CBr FUKOTTQGWQVMQB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- AOTQGWFNFTVXNQ-UHFFFAOYSA-N 2-(1-adamantyl)acetic acid Chemical compound C1C(C2)CC3CC2CC1(CC(=O)O)C3 AOTQGWFNFTVXNQ-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 1
- 108010065026 HLA-DQB1 antigen Proteins 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000979735 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 102100024975 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial Human genes 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000005864 bromoacetylation reaction Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- HJZLEGIHUQOJBA-UHFFFAOYSA-N cyclohexane propionic acid Chemical compound OC(=O)CCC1CCCCC1 HJZLEGIHUQOJBA-UHFFFAOYSA-N 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 108700007621 mifamurtide Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Plant Pathology (AREA)
- Rehabilitation Therapy (AREA)
Description
CYCLIC PEPTIDE VACCINES FOR TREATMENT AND PREVENTION OF DIABETES
CROSS REFERENCE TO RELATED APPLICATIONS This is a continuation in part of USSN 60/014,790, which is incorporated herein by reference.
BACKGROUND OF THE INVENTION The present invention relates to novel compositions and methods for inhibiting immune responses associated with autoimmune diseases. In particular, it relates to vaccination with peptides from hypervariable regions of MHC molecules associated with insulin dependent diabetes mellitus (IDDM).
IDDM is the result of selective destruction of the insulin-producing β cells in the pancreas (see, e.g. , Eisenbarth, N. Engl. J. Med. 314: 1360-1368 (1986) and Reich, et ul. , Diabetes Reviews 1 :293 (1993)). Insulin regulates the cellular uptake and metabolism of glucose, and its deficiency leads to hyperglycemia diabetic acidosis, and diabetic coma. The disease usually appears in individuals before the age of 20 and affects about 0.5% of the Caucasian population worldwide.
Current therapeutic approaches aimed at prevention of IDDM are based on non-antigen-specific inhibition of T cells (e.g. , cyclosporin A) or by providing β cell rest (e.g. , parenteral administration of insulin). In patients who already have diabetes, transplantation of the pancreas or insulin producing β cells is also being explored.
These prior art methods fail to provide a simple self-mediated method for specifically eliminating immune responses restricted by glycoproteins encoded by MHC alleles associated with the autoimmune response associated with IDDM. Because autoreactive T cells are responsible for the anti-β cell attack which leads to diabetes, therapeutic strategies which intervene at the stage of TCR engagement would be particularly useful. The present invention addresses these and other needs.
SUMMARY OF THE INVENTION The present invention provides methods of inducing an immune response against an HLA molecule associated with IDDM , such as HLA-DQ molecules. The methods comprise administering to a patient an immunologically effective amount of a pharmaceutical composition comprising an adjuvant and a cyclic immunogenic MHC polypeptide from a hypervariable region of a HLA-DQ molecule, typically, the β chain of the HLA-DQ molecule. The peptides include from about 10 to about 50 residues, but typically consist of about 20 to about 30 residues. A preferred peptide comprises amino acid residues 57-78 of a protein encoded by DQB1 *0302. A particularly preferred peptide is CAAEYWNSQKEVLERTRAELDTVC.
The peptides may be administered according to standard protocols, typically by parenteral administration. An adjuvant such as alum may be included. The compositions of the invention may be administered prophylactically or therapeutically. For instance, the compositions can be administered to pre-diabetics to prevent or ameliorate the onset of symptoms.
Definitions The term "peptide" is used interchangeably with "oligopeptide" or "polypeptide" in the present specification to designate a series of residues, typically L- amino acids, connected. one to the other typically by peptide bonds between the α-amino and carbonyl groups of adjacent amino acids.
The term "cyclic peptide" refers to peptides in which the N-terminal residue is linked to the C-terminal residue either directly or through an intermediate. Examples of links between the two residues include disulfide bonds and thioether linkages as described below.
An "immunogenic MHC polypeptide" of the present invention is a polypeptide capable of eliciting an immune response against an MHC molecule associated with a deleterious immune response in a patient, such as IDDM. As set forth in more detail below, the sequence of residues in the polypeptide will be identical to or substantially identical to a polypeptide sequence in the MHC molecule. Thus, a polypeptide of the invention that has a sequence "from a hypervariable region of an HLA- DQ molecule" is polypeptide that has a sequence either identical to or substantially
identical to the naturally occurring MHC amino acid sequence of the region.
As used herein a "hypervariable region" of an MHC molecule is a region of the molecule in which polypeptides encoded by different alleles at the same locus have high sequence variability or polymorphism. The polymoφhism is typically concentrated in the αl and α2 domains of Class I molecules and in the αl and β l domains of Class II molecules. The number of alleles and degree of polymoφhism among alleles may vary at different loci. For instance, in HLA-DR molecules all the polymoφhism is attributed to the β chain and the chain is relatively invariant. For HLA-DQ, both the α and β chains are polymoφhic. For instance, a hypervariable region spanning residues 57 through 78 of the DQ β chain can be used. For a description of hypervariable regions in various HLA gene products see, Fundamental Immunology, supra.
As used herein, the term "adjuvant" refers to any substance which, when administered with or before an antigen, increases and/or qualitatively affects the immune response against the antigen in terms of antibody formation and/or the cell-mediated response. Exemplary adjuvants for use in the present invention are provided below.
The phrases "isolated" or "biologically pure" refer to material which is substantially or essentially free from components which normally accompany it as found in its native state. Thus, the MHC polypeptides of this invention do not contain materials normally associated with their in situ environment, e.g. , other surface proteins on antigen presenting cells. Even, where a protein has been isolated to a homogenous or dominant band, there are trace contaminants in the range of 5-10% of native protein which co-purify with the desired protein. Isolated polypeptides of this invention do not contain such endogenous co-purified protein.
The term "residue" refers to an amino acid or amino acid mimetic incoφorated in a oligopeptide by an amide bond or amide bond mimetic.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows the amino acid sequence of the third hypervariable region of various human and murine Class II β chains. Figure 2 shows the percent diabetes in NOD mice treated with various doses of cyclic peptides of the invention.
Figure 3 shows the results of ELISA analysis of serum derived from mice
treated with peptides of the invention.
Figure 4 shows the results of ELISA analysis of serum derived from mice treated with peptides of the invention.
Figure 5 shows the results of ELISA analysis of serum derived from mice treated with peptides of the invention using different boosting regimens.
Figure 6 shows the results of analysis of T cell reactivity in mice treated with peptides of the invention.
DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention provides immunogenic polypeptides derived from
MHC glycoprotein protein sequences for use in compositions and methods for the treatment, prevention and diagnosis of IDDM. The polypeptides are capable of inducing an immune response against glycoproteins encoded by MHC alleles associated with the disease. In preferred embodiments the polypeptides of the invention are cyclized and derived from hypervariable regions of the a or β chain of an HLA-DQ molecule.
The glycoproteins encoded by the MHC have been extensively studied in both the human and murine systems. Many of the histocompatibility proteins have been isolated and characterized. For a general review of MHC glycoprotein structure and function, see Fundamental Immunology, .supra. MHC molecules are heterodimeric glycoproteins expressed on cells of higher vertebrates and play a role in immune responses. In humans, these molecules are referred to as human leukocyte antigens (HLA). MHC glycoproteins are divided into two groups, class I and class II, which differ structurally and functionally from each other. In general, the major function of MHC molecules is to bind antigenic peptides and display them on the surface of cells.
Human MHC Class II molecules are encoded by genes in the HLA-DR, - DP, and -DQ subregions. These glycoproteins comprise two chains, the α and β chains, which extend from the membrane bilayer. Each subunit in MHC Class II molecules consist of globular domains, referred to as αl , α2, β l , and β2. All except the αl domain are stabilized by intra-chain disulfide bonds typical of molecules in the immunoglobulin superfamily. The N-terminal portions of the α and β chains, the αl and βl domains, contain hypervariable regions which are thought to comprise the majority of the antigen-
binding sites (sec, Brown et al. , Nature 364:33-39 (1993)).
The HLA-DQ subregion contains two genes encoding α chains (DQA1 and DQA2) and three genes encoding β chains (DQB1 , DQB2, and DQB3). The DQA1 and DQB1 genes encode the HLA-DQ molecule, while the other genes are pseudogenes. As noted above, each MHC allele encodes proteins which comprise hypervariable regions and antigen binding sites specific for particular sets of antigenic peptides. If the peptides bound by the MHC molecule are from an autoantigen, allergen or other protein associated with a deleterious immune response, the hypervariable region of the MHC molecule can be used to produce immunogenic polypeptides which will elicit an immune response against the MHC molecule. These polypeptides are therefore useful in targeting particular gene products associated with deleterious immune responses because the immune response against the MHC molecule will inhibit antigen presentation associated with the deleterious immune response (see, PCT application No. US93/12351). Thus, immunization with the polypeptides will be haplotype specific and result only in the inhibition of the immune response mediated by the target molecules, while leaving other alleles unaffected. Most individuals are heterozygous at each MHC locus. Therefore, haplotype specific therapy of disease by immunization with polypeptides of the disease susceptibility gene products of MHC genes offers a novel means of immunotherapy. For the treatment of humans, peptides from the hypervariable regions of
HLA molecules associated with IDDM are used. A number of HLA alleles are associated with IDDM. These include DR4, DR3, and DQ. For a discussion of the association of various HLA alleles with IDDM, see, Green, Current Topics in Microbiology and Immunology 164:3 (1990), Todd, Current Topics in Microbiology and Immunology 164: 17 (1990), Erlich, Current Topics in Microbiology and Immunology 164:41 (1990),
Michelsen et al , Current Topics in Microbiology and Immunology 164:57 (1990), and Lo, Current Topics in Microbiology and Immunology 164:71 (1990). The peptides of the invention are preferably from the hypervariable region of an HLA-DQB1 molecule.
In the example below, a peptide consisting of residues 56-77 (in which the histidine at residue 56 is replaced by cysteine) of the murine MHC class II I-A*7 β sequence is used as the immunogen. This synthetic peptide has the following sequence: I-Ag7 β 56-57 C56 C-S-A-E-Y-Y-N-K-Q-Y-L-E-R-T-R A-E-L-D-T-A-C-NH2
DQB1 is the human equivalent of the murine I-Ag7 β chain gene. A comparison of the sequences the third hypervariable region of human and murine Class II β chains is shown in Figure 1. A preferred peptide is one from the third hypervariable region of DQB 1 *0302. An exemplary peptide comprises the following sequence.
A-A-E-Y-W-N-S-Q-K-E-V-L-E-R-T-R A-E-L-D-T-V
In preferred embodiments, the peptides of the invention are cyclized. Methods for cyclizing peptides are described in detail below. In those cases in which the peptides are cyclized by disulfide linkages, one of skill will recognize that the peptides will further comprise cysteine residues either within the peptide or at each terminus.
Polypeptides suitable for use in the present invention can be obtained in a variety of ways. Conveniently, they can be synthesized by conventional techniques employing automatic synthesizers, such as the Beckman, Applied Biosystems, or other commonly available peptide synthesizers using well known protocols. They can also be synthesized manually using techniques well known in the art. See, e.g. Stewart and Young, Solid Phase Peptide Synthesis, (Rockford, 111. , Pierce), 2d Ed. (1984). Alternatively, DNA sequences which encode the particular MHC polypeptide may be cloned and expressed to provide the peptide. Cells comprising a variety of MHC genes are readily available, for instance, they may be obtained from the
American Type Culture Collection ("Catalogue of Cell Lines and Hybridomas," 6tn edition (1988) Rockville, Maryland, U.S.A. The National Institute of General Medical Sciences Catalog of Cell Lines (NIGMS) Human Genetic Mutant Cell Repository, Camden, NJ; and ASHI Repository, Bingham and Women's Hospital, 75 Francis Street, Boston, MA 021 15 are also useful sources. Cell lines expressing appropriate DQ alleles include GMO6824A (DQB 1 *0201 ) and GM06821 A (DQB 1 *0302), both of which are available from NIGMS.
Standard techniques can be used to screen cDNA libraries to identify sequences encoding the desired sequences (see, Sambrook et al. , Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989). Fusion proteins (those consisting of all or part of the amino acid sequences of two or more proteins) can be recombinantly produced. In addition, using in vitro mutagenesis techniques, unrelated proteins can be mutated to comprise the appropriate sequences.
MHC glycoproteins from a variety of natural sources are also conveniently isolated using standard protein purification techniques. Peptides can be purified by any of a variety of known techniques, including, for example, reverse phase high-performance liquid chromatography (HPLC), ion-exchange or immunoaffinity chromatography, separation by size, or electrophoresis (See, generally, Scopes, R. , Protein Purification, Springer-Verlag, N. Y. (1982)).
It will be understood that the immunogenic MHC polypeptides of the present invention may be modified to provide a variety of desired attributes, e.g., improved pharmacological characteristics, while increasing or at least retaining substantially all of the biological activity of the unmodified peptide. For instance, the peptides can be modified by extending, decreasing the amino acid sequence of the peptide. Substitutions with different amino acids or amino acid mimetics can also be made.
The peptides employed in the subject invention need not be identical to peptides disclosed in the Example section, below, so long as the subject peptides are able to induce an immune response against the desired MHC molecule. Thus, one of skill will recognize that a number of conservative substitutions (described in more detail below) can be made without substantially affecting the activity of the peptide.
Single amino acid substitutions, deletions, or insertions can be used to determine which residues are relatively insensitive to modification. Substitutions are preferably made with small, relatively neutral moieties such as Ala, Gly, Pro, or similar residues. The effect of single amino acid substitutions may also be probed using D-amino acids. The number and types of residues which are substituted or added depend on the spacing necessary between essential contact points and certain functional attributes which are sought (e.g. , hydrophobicity versus hydrophilicity). Increased immunogenicity may also be achieved by such substitutions, compared to the parent peptide. In any event, such substitutions should employ amino acid residues or other molecular fragments chosen to
avoid, for example, steric and charge interference which might disrupt binding.
The substituting amino acids, however, need not be limited to those naturally occurring in proteins, such as L-α-amino acids, or their D-isomers. The peptides may be substituted with a variety of moieties such as amino acid mimetics well known to those of skill in the art.
The individual residues of the immunogenic MHC polypeptides can be incoφorated in the peptide by a peptide bond or peptide bond mimetic. A peptide bond mimetic of the invention includes peptide backbone modifications well known to those skilled in the art. Such modifications include modifications of the amide nitrogen, the α- carbon, amide carbonyl, complete replacement of the amide bond, extensions, deletions or backbone crosslinks. See, generally, Spatola, Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. VII (Weinstein ed. , 1983). Several peptide backbone modifications are known, these include, ψ[CH2S], ψ[CH2NH], ψ[CSNH2], ψ[NHCO], ψ[C0CH2] and ψ[(E) or (Z) CH=CH]. The nomenclature used above, follows that suggested by Spatola, above. In this context, ψ indicates the absence of an amide bond.
The structure that replaces the amide group is specified within the brackets.
Amino acid mimetics may also be incoφorated in the peptides. An "amino acid mimetic" as used here is a moiety other than a naturally occurring amino acid that con formation ally and functionally serves as a substitute for an amino acid in a polypeptide of the present invention. Such a moiety serves as a substitute for an amino acid residue if it does not interfere with the ability of the peptide to illicit an immune response against the appropriate MHC molecule. Amino acid mi .ietics may include non-protein amino acids, such as β-γ-δ-amino acids, β-γ-δ-imino acids (such as piperidine-4-carboxylic acid) as well as many derivatives of L-α-amino acids. A number of suitable amino acid mimetics are known to the skilled artisan, they include cyclohexylalanine, 3-cyclohexylpropionic acid, L-adamantyl alanine, adamantylacetic acid and the like. Peptide mimetics suitable for peptides of the present invention are discussed by Morgan and Gainor, (1989) Ann. Repts. Med. Chem. 24:243-252/
As noted above, the peptides employed in the subject invention need not be identical, but may be substantially identical, to the corresponding sequence of the target MHC molecule. Therefore, the peptides may be subject to various changes, such as insertions, deletions, and substitutions, either conservative or non-conservative, where
such changes might provide for certain advantages in their use. The polypeptides of the invention can be modified in a number of ways so long as they comprise a sequence substantially identical (as defined below) to a sequence in the target region of the MHC molecule. Alignment and comparison of relatively short amino acid sequences (less than about 30 residues) is typically straightforward. Comparison of longer sequences may require more sophisticated methods to achieve optimal alignment of two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol.
48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. (USA) 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr. , Madison, WI), or by inspection, and the best alignment (i.e. , resulting in the highest percentage of sequence similarity over the comparison window) generated by the various methods is selected.
The term "sequence identity" means that two polynucleotide sequences are identical (i.e. , on a nucleotide-by-nucleotide basis) over a window of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical residues occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e. , the window size), and multiplying the result by 100 to yield the percentage of sequence identity. As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity or more (e.g. , 99 percent sequence identity). Preferably, residue positions which are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and
isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine- isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine- glutamine.
The polypeptides of the invention typically comprise at least about 10 residues and more preferably at least about 15 residues. In certain embodiments the peptides will not exceed about 50 residues and typically will not exceed about 30 residues. For instance, the DQB 1*0302 peptides described below consist of 22 residues with out the additional cysteine residues at each end. In other embodiments, the entire subunit (α or β chain) or large portions of the molecules are used. For instance, the polypeptides can comprise an extracellular domain from an MHC subunit (about 90-100 residues).
Typically, the N-terminal domain (β l or αl) is used. The entire extracellular region (e.g. , βl and β2 or αl and α2 of class II molecules or αl , α2 and α3 of class I molecules) from the subunit can also be used. Thus, a wide range of polypeptide sizes may be used in the present invention. In the preferred embodiments of the invention, the immunogenic peptides are cyclized. Any method commonly used to produce cyclized oligopeptides can be used to produce the peptides of the invention. For example, in certain embodiments the peptides will include cysteine residues at both termini, which allow the production of cyclic peptides through disulfide linkages. Treatment of a such a peptide with an oxidizing agent such as oxygen, iodine or similar agent will produce a cyclic peptide which may be further purified using chromatographic or other methods of chemical purification. Construction of cyclic peptides can also be accomplished through thioether linkages. For instance, N-bromoacetyl-derivatized peptides can be reacted with sulfhydryl-containing residues, such as cysteine. Cyclization occurs by reaction of the free sulfhydryl of cysteine in the peptide with the bromoacetyl group to form a thioether linkage (Robey ct al , Anal. Biochem. 177:373-7 ( 1989) and U.S. Patent No. 5,066,716).
Other methods of constructing cyclic peptides are known to those skilled in
the art. These include side chain-side chain, side chain-main chain and main chain-main chain cyclizations. In addition, linkers can be used to join the amino and carboxyl termini of a peptide. The linker is capable of forming covalent bonds to both the amino and carboxyl terminus. Suitable linkers are well known to those of skill in the art and include, but are not limited to, straight or branched-chain carbon linkers, heterocyclic carbon linkers, or peptide linkers. The linkers may be joined to the carboxyl and amino terminal amino acids through their side groups (e.g. , through a disulfide linkage to cysteine) or through the alpha carbon amino and carboxyl groups of the terminal amino acids. For a general discussion of suitable methods for cyclization see , Hruby and
Bonner in Methods in Molecular Biology, Volume 35: Peptide Synthesis Protocols Pennington and Dunn eds (Humana Press, Totowa NJ, 1994). For instance, cyclizations may include formation of carba analogs and thioethers (Lebl et al. in Peptides 1986 Proceedings of the 19th European Peptide Symposium pp. 341-344; Robey et al. , Anal. Biochem. 177:373-7 (1989) and U.S. Patent No. 5,066,716), bis-thioethers (Mosberg et al. JACS 107:2986-2987 (1985)), azopeptides (Siemion et al. Mol. Cell. Biochem. 34: (1991)), and other cyclic structures, such as bridging structures (Chaφentier, M. , et al. , J. Med. Chem. 32(6): 1 184- 1 190 (1989), Thaisrivongs, S. , et al. , J. Med. Chem. 34(4): 127 (1991) and Ozeki, E. , et al . Int. J. Peptide Protein Res. 34: 11 1 (1989)). Cyclization from backbone-to-backbone positions may also be used.
Bridging is a special type of cyclization in which distant sites in a peptide are brought together using separate bridging molecules or fragments. Bridging molecules may include, for example, succinic anhydride molecules (Chaφentier, B. , et al. , supra), and carboxymethylene fragments (Thaisrivongs, S. , et al. , supra). Bridging by metals can also be used (Ozeki, E., et ai. , supra).
In some embodiments, the peptides include two or more cystine residues. The cystines can be substituted or added within the peptide or at either terminus. The position of the cystines is not critical so long as disulfide linkages can form between them which allow the production of cyclic peptides. For example, treatment of such a peptide with an oxidizing agent such as oxygen, iodine or similar agent will produce a cyclic peptide which may be further purified using chromatographic or other methods of chemical purification.
In addition to use of peptides, antibodies raised against peptides of the invention can be used to inhibit autoimmune responses, such as IDDM. Antibodies can be raised to the peptides of the present invention using techniques well known to those of skill in the art. Anti-idiotypic antibodies can also be generated. The following discussion is presented as a general overview of the techniques available; however, one of skill will recognize that many variations upon the following methods are known.
A number of immunogens can be used to produce antibodies specifically reactive with the peptides. For instance, the entire MHC molecule or fragments containing the desired sequence can be used. Synthetic peptides as disclosed here can be used either in linear form or cyclized.
Methods of producing polyclonal antibodies are known to those of skill in the art. In brief, an immunogen (antigen), preferably a purified polypeptide, a polypeptide coupled to an appropriate carrier (e.g. , GST, keyhole limpet hemanocyanin, etc.), or a polypeptide incoφorated into an immunization vector such as a recombinant vaccinia virus (see, U.S. Patent No. 4,722,848) is mixed with an adjuvant and animals are immunized with the mixture. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to the polypeptide of interest. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the polypeptide is performed where desired
(see, e.g. , Coligan (1991) Current Protocols in immunology Wiley/Greene, NY; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press, NY).
In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies are found in, e.g. , Stites et al. (eds.) Basic and Clinical Immunology (4th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane, Supra; Coding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press, New York, NY; and Kohler and Milstein (1975) Nature 256: 495-497. Summarized briefly, this method proceeds by injecting an animal with an immunogen. The animal is then sacrificed and cells taken from its spleen, which are fused with myeloma cells. The result is a hybrid cell or
"hybridoma" that is capable of reproducing in vitro. The population of hybridomas is then screened to isolate individual clones, each of which secrete a single antibody species to the immunogen. In this manner, the individual antibody species obtained are the products of immortalized and cloned single B cells from the immune animal generated in response to a specific site recognized on the immunogenic substance.
Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells is enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate (preferably mammalian) host. Specific monoclonal and polyclonal antibodies will usually bind with a K,, of at least about . 1 mM, more usually at least about 50 μM, and most preferably at least about 1 μM or better.
Other suitable techniques involve selection of libraries of recombinant antibodies in phage or similar vectors (see, e.g. , Huse et al. (1989) Science 246: 1275- 1281 ; and Ward, et al. (1989) Nature 341 : 544-546; and Vaughan et al. (1996) Nature Biotechnology, 14: 309-314).
Frequently, the peptides and antibodies of the invention will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionucleotides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275, 149; and 4,366,241. Also, recombinant immunoglobulins may be produced. See, Cabilly, U.S. Patent No. 4,816,567; and Queen et al. (1989) Proc. Nat' I Acad. Sci. USA 86: 10029- 10033.
The antibodies of this invention can also be administered to an organism (e.g. , a human patient) for therapeutic puφoses (e.g. , to inhibit an autoimmune response). Antibodies administered to an organism other than the species in which they are raised are often iminunogenic. Thus, for example, murine antibodies administered to a human often induce an immunologic response against the antibody (e.g. , the human anti-mouse
antibody (HAMA) response) on multiple administrations. The immunogenic properties of the antibody are reduced by altering portions, or all, of the antibody into characteristically human sequences thereby producing chimeric or human antibodies, respectively.
Chimeric antibodies are immunoglobulin molecules comprising a human and non-human portion. More specifically, the antigen combining region (or variable region) of a humanized chimeric antibody is derived from a non-human source (e.g. , murine) and the constant region of the chimeric antibody (which confers biological effector function to the immunoglobulin) is derived from a human source. The chimeric antibody should have the antigen binding specificity of the non-human antibody molecule and the effector function conferred by the human antibody molecule. A large number of methods of generating chimeric antibodies are well known to those of skill in the art (see, e.g. , U.S. Patent Nos: 5,502, 167, 5,500,362, 5,491 ,088, 5,482,856, 5,472,693, 5,354,847, 5,292,867, 5,231,026, 5,204,244, 5,202,238, 5, 169,939, 5,081 ,235, 5,075,431 , and 4,975,369). An alternative approach is the generation of humanized antibodies by linking the CDR regions of non-human antibodies to human constant regions by recombinant
DNA techniques. See Queen et al. , Proc. Natl. Acad. Sci. USA 86: 10029-10033 (1989) and WO 90/07861.
In one preferred embodiment, recombinant DNA vector is used to transfect a cell line that produces an antibody against a peptide of the invention. The novel recombinant DNA vector contains a "replacement gene" to replace all or a portion of the gene encoding the immunoglobulin constant region in the cell line (e.g. , a replacement gene may encode all or a portion of a constant region of a human immunoglobulin, or a specific immunoglobulin class), and a "target sequence" which allows for targeted homologous recombination with immunoglobulin sequences within the antibody producing cell.
In another embodiment, a recombinant DNA vector is used to transfect a cell line that produces an antibody having a desired effector function, (e.g. , a constant region of a human immunoglobulin) in which case, the replacement gene contained in the recombinant vector may encode all or a portion of a region of an antibody and the target sequence contained in the recombinant vector allows for homologous recombination and targeted gene modification within the antibody producing cell. In either embodiment, when only a portion of the variable or constant region is replaced, the resulting chimeric
antibody may define the same antigen and/or have the same effector function yet be altered or improved so that the chimeric antibody may demonstrate a greater antigen specificity, greater affinity binding constant, increased effector function, or increased secretion and production by the transfected antibody producing cell line, etc. In another embodiment, this invention provides for fully human antibodies.
Human antibodies consist entirely of characteristically human polypeptide sequences. The human antibodies of this invention can be produced in using a wide variety of methods (see, e.g. , Larrick et al. , U.S. Pat. No. 5,001 ,065). In one preferred embodiment, the human antibodies of the present invention are produced initially in trioma cells. Genes encoding the antibodies are then cloned and expressed in other cells, particularly, nonhuman mammalian cells. The general approach for producing human antibodies by trioma technology has been described by Ostberg et al. (1983), Hybridoma 2: 361-367, Ostberg, U.S. Pat. No. 4,634,664, and Engelman et al. , U.S. Pat. No. 4,634,666. The antibody-producing cell lines obtained by this method are called trioinas because they are descended from three cells; two human and one mouse. Triomas have been found to produce antibody more stably than ordinary hybridomas made from human cells.
Model Systems for In vivo Testing
An animal model for spontaneous IDDM and thyroiditis has been developed in the BB rat (see, e.g. , Rossini et al. Autoimmunity 8:221-235 (1991)). As in humans, the rat disease is controlled in part by the genes encoding the MHC antigens, is characterized by islet infiltration, and is associated with the presence of anti-islet antibodies. The I-E equivalent Class II MHC antigens appear to be involved in manifestation of the autoimmune diseases in the BB rat. Biotard, et al. , Proc. Natl. Acad. Sci. USA 82:6627 (1985).
In another spontaneous model, the NOD mouse strain (H-2g7) is a murine model for autoimmune IDDM. The disease in these animals is characterized by anti-islet cell antibodies, severe insulitis, and evidence for autoimmune destruction of the β-cells. Kanazawa, et al. , Diabetologia ( 1984) 27: 1 13. The disease can be passively transferred with lymphocytes and prevented by treatment with cyclosporin-A (Ikehara, et al. , Proc.
Natl. Acad. Sci. USA ( 1985) 82:7743; Mori, et al.), Diabetologia ( 1986) 29:244. Untreated animals develop profound glucose intolerance and ketosis and succumb within
16 weeks of the onset of the disease. Seventy to ninety percent of female and 20-30% of male animals develop diabetes within the first six months of life. Breeding studies have defined at least two genetic loci responsible for disease susceptibility, one of which maps to the MHC. Characterization of NOD Class II antigens at both the serologic and molecular level suggest that the susceptibility to autoimmune disease is linked to I-Aβ.
Baxter et al. Autoimmuniry 9:61-67 (1991) and Kikutani et al. Adv. Immunol. 51 :285 (1992).
Formulation and Administration
The peptides or antibodies (typically monoclonal antibodies) of the present invention and pharmaceutical compositions thereof are useful for administration to mammals, particularly humans, to treat and/or prevent deleterious immune responses. Suitable formulations are found in Remington 's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed. ( 1985).
The immunogenic peptides or antibodies of the invention are administered prophylactically or to an individual already suffering from the disease. In particular, the composition of the invention can be administered to pre-diabetics or early stage diabetics. In addition, first degree relatives of IDDM patients can now be screened for autoantibodies to three common islet cell antigens, GAD, ICS and IA-2. Those testing positive in these or other diagnostic assays can be treated with the compositions of the present invention. In this way the onset of the disease symptoms can be prevented or ameliorated.
The peptide compositions are administered to a patient in an amount sufficient to elicit an effective immune response to the MHC molecule from which the peptides are derived. An amount adequate to accomplish this is defined as "therapeutically effective dose" or "immunogenically effective dose. " Amounts effective for this use will depend on, e.g., the peptide composition, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of ' ie patient, and the judgment of the prescribing physician, but generally range for the initial immunization (that is for therapeutic or prophylactic administration) from about 0.1 mg to about 1.0 mg per 70 kilogram patient, more commonly from about 0.5 mg to about 0.75 mg per 70 kg of body weight. Boosting dosages are typically from about 0. 1 mg to about 0.5 mg of peptide using a boosting regimen over weeks to months depending upon
17 the patient's response and condition. A suitable protocol would include injection at time 0, 4, 2, 6, 10 and 14 weeks, followed by further booster injections at 24 and 28 weeks. It must be kept in mind that the peptides and compositions of the present invention may generally be employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, in view of the minimization of extraneous substances and the relative nontoxic nature of the peptides, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions.
For therapeutic use, administration should begin at the first sign of autoimmune disease. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. In some circumstances, loading doses followed by boosting doses may be required. The resulting immune response helps to cure or at least partially arrest symptoms and/or complications. Vaccine compositions containing the peptides are administered prophylactically to a patient susceptible to or otherwise at risk of the disease to elicit an immune response against the target MHC antigen.
The pharmaceutical compositions (containing either peptides or antibodies) are intended for parenteral or oral administration. Preferably, the pharmaceutical compositions are administered parenterally, e.g. , subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g. , water, buffered water, 0.4 % saline, 0.3 % glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or Iyophilized, the Iyophilized preparation being combined with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incoφorating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25% -75%
As noted above, the peptide compositions are intended to induce an immune response to the peptides Thus, compositions and methods of administration suitable for maximizing the immune response are preferred For instance, peptides may be introduced into a host, including humans, linked to a carrier or as a homopolymer or heteropolymer of active peptide units Alternatively, the a "cocktail" of polypeptides can be used A mixture of more than one polypeptide has the advantage ol increased immunological reaction and, where different peptides are used to make up the polymer, the additional ability to induce antibodies to a number ot epitopes For instance, polypeptides comprising sequences from hypervariable regions of α and β chains may be used in combination Useful carriers are well known in the art, and include, e.g , KLH, thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly(lysιne:glutamιc acid), influenza, hepatitis B virus core protein, hepatitis B virus recombinant vaccine and the like
The use of more than one polypeptide is particularly useful to enhance the immune response against polypeptides of the invention. As demonstrated below, although the polypeptides may be derived from selt MHC molecules expressed in the patient, they can induce an immune response In some instances, the immune response to the self polypeptide may not be sufficiently strong In these instances, it may be necessary to break tolerance to the polypeptide The compositions may comprise one or more of the foreign polypeptides that are sufficiently similar to the self polypeptides to induce an immune response against both the foreign and self polypeptides (see, Mamula et al. J. Immunol 149.789-795 (1992) Suitable proteins include synthetic polypeptides designed for this piiφose or polypeptide sequences trom homologous proteins from natural sources, such as proteins encoded by a different allele at the same locus as the self polypeptide
The compositions also include an adjuvant. As used here, number of adjuvants are well known to one skilled in the art. Suitable adjuvants include incomplete Freund's adjuvant, alum, aluminum phosphate, aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP),
N-acetylmuramyl-Lalanyl-D-isoglutaminyl-L-alanine-2-( -2'-dipalmitoyl-sn- glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835 A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM +CWS) in a 2% squalene/Tween 80 emulsion. The effectiveness of an adjuvant may be determined by measuring the amount of antibodies directed against the immunogenic peptide.
A particularly useful adjuvant and immunization schedule are described in Kwak et al. New Eng. J. Med. 327-1209- 1215 ( 1992). The immunological adjuvant described there comprises 5% (wt/vol) squalene, 2.5 % Pluronic L121 polymer and 0.2 % polysorbate in phosphate buffered saline.
The concentration of immunogenic peptides of the invention in the pharmaceutical formulations can vary widely, i.e. from less than about 0. 1 % , usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc. , in accordance with the particular mode of administration selected.
The peptides of the invention can also be expressed by attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus as a vector to express nucleotide sequences that encode the peptides of the invention. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g. , U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al. (Nature 351 :456-460 (1991)). A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e.g. , Salmonella typhi vectors and the like, will be apparent to those skilled in the art from the description herein.
The DNA encoding one or more of the peptides of the invention can also be administered to the patient. This approach is described, for instance, in Wolff et. al. , Science 247: 1465-1468 (1990) as well as U.S. Patent Nos. 5,580,859 and 5,589,466.
In order to enhance serum half-life, the peptides may also be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques may be employed which provide an extended serum half-life of the peptides. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka et al. , Ann. Rev. Biophys. Bioeng. 9:467 (1980), U.S. Pat. Nos. 4, 235,871 , 4,501 ,728 and 4,837,028. The peptides or antibodies of the invention can also be used for diagnostic puφoses. For instance, peptides can be used to screen for autoantibodies to ensure that the vaccination has been effective. Antibodies can be used to detect the presence of particular MHC molecules associated with disease.
The following examples are offered by way of illustration, not by way of limitation.
Example 1 This example describes the use of cyclized peptides from the murine I-Ag7 β chain (including amino acids 56-77). The I-A*17 β 56-77 C56 peptide sequence is from the third hypervariable region of NOD mouse MHC class II I-Ap7 with a cysteine replacing the histidine at the position 56. This synthetic peptide has the following sequence:
I-Ag7 β 56-77 C56 C-S-A-E-Y-Y-N-K-Q-Y-L-E-R-T-R-A-E-L-D-T-A-C-NH2
Synthesis and characterization of the cyclic peptide
The linear peptide I-Ag7β56-77C56 was synthesized by Merrifield solid phase peptide synthesis (SPPS) on an automated peptide synthesizer (433 A Applied Biosystems, Foster City USA) generally as described by Luu et al. Inf. J. Peptide Protein Res. 47:91-96 (1996). The peptide was assembled from carboxy terminal end at 0.25 millimole scale on Rink amide MBHA resin (substitution level 0.55 millimoles per gram).
HOBt/HBTU coupling strategy was used for acylation of amines on the resin and piperidine was used for the deprotection of Fmoc protected α-amine of the amino acid on the resin. The side chain protection strategy is given in Table 1. Our earlier studies indicated coupling problems after the 7 the residue from the C terminus and therefore a double coupling of amino acids was carried out after the seventh residue.
N-methylpyrrohdinone (NMP) was used as solvent for coupling/deprotection reactions and dichloromethane(DCM) was used for final washing of peptide resin. The deprotection was monitored by measuring the conductivity of Fmoc released.
Table 1. Side chain protecting groups used in the peptide synthesis.
Amino Acid Side Chain Protecting Group
S, T, Y, D, and E t-Butyl (t-Bu)
R 2,3,5,7,8-Pentamethyl-chloraman-6-sulfonyl
(Pme)
K, and W Butyloxycarbonyl (Boc)
After successful assembly of the peptide chain on the resin, the peptide resin was dried in vacuum for 2 hours and subjected peptide cleavage protocol. The resin was suspended in 10 ml of trifluoroacetic acid(TFA) containing 0.6 g of
4-methylmercaptophenol and 1 ml of 4-methoxybenzenethiol . The suspension was mixed for 2 hours at room temperature and then filtered into 1000 ml of organic solvent(pentane: acetone 4: 1). The precipitate was allowed to settle for 2 hours at room temperature. The clear solvent was removed by decantation and centrifugation. The precipitate was washed with pentane acetone mixture (50 ml each time 5 times) and finally with pentane (50 ml twice). The crude linear peptide was dried in vacuum for 1 hour. It was subjected to reverse phase HPLC using a C 18 column.
Cyclization of the crude peptide:
The crude linear peptide (100 mg) was dissolved in 100 ml of 0.5 % acetic acid containing 15% acetonitrile. Two grams of commercially available intramolecular disulfide bond forming resin (Ekathiox from Ekagen Coφ. San Carlos, CA) was mixed
with it and the suspension was gently tumbled overnight at room temperature. The formation of cyclic peptide was monitored by HPLC and estimation of free SH groups in solution by Ellman Reagent. The resin was removed by filtration and the filtrate was used for isolation of cyclic peptide.
The crude cyclic peptide solution obtained above was directly loaded on HPLC with C18 reverse phase column. The cyclic peptide was eluted using acetonitrile water gradient. The pure fractions as indicated by HPLC were poled and Iyophilized and the pure cyclized peptide was characterized by HPLC, Amino acid analysis and mass spectrometry. The peptides were stored at -20°C until they were used.
Example 2 This example describes animal studies using the peptides described in Example 1. In vivo studies to demonstrate the ability of the cyclic 1-As7 peptide vaccine to protect NOD mice from IDDM were carried out. The entire project was divided into low dose, mid dose, and high dose studies as follows.
Low Dose: Treatment group/mouse n≡.
5μg peptide/ 150 μl Alum 5
50μg peptide/ 150 μl Alum 5
150μ Alum 5
150μl PBS 5
Mid Dose:
Treatment group/mouse n≡.
50μg peptide/ 150 μl Alum 5 lOOμg peptide/ 150 μl Alum 10 200μg peptide/ 150 μl Alum 7
150μl Alum 10
150μl PBS 5
High dose:
Treatment group/ mouse H
400μg peptide/ 150 μl Alum 600μg peptide/ Alum
Mice were administered treatment in three subcutaneous dorsal sites. The peptide was emulsified in an Alum adjuvant; which had previously been demonstrated not to cause protection from or delay the onset of diabetes in the NOD mouse (data not shown). For each treatment group, the initial injection was at 5 weeks of age, and was followed by three boosts at intervals of 2-3 weeks, with the final injection taking place at 12 weeks of age. Screening for diabetes was begun at 12 weeks of age, and was performed by urinalysis with Ames Glucose Diastix according to the manufacturer's instructions (Ames, Elkhart, IN). The results of these experiments are shown in Figure 2. There it can be seen that at dose levels of 50 μg and above, statistically significant protection against diabetes as compared to controls (Alum alone) was observed.
Western blot analysis was used to determine the reactivity of antiserum from the mice 24 weeks after immunization with the peptides. These results showed that antiserum from mice receiving 50, 100 and 200 μg of peptide, was reactive with the IA 7 β chain, whereas control serum from untreated NOD mice showed no reactivity.
In addition ELISA analysis was performed to test the reactivity of the antiserum from the mice. Plates were coated with a linear peptide from IAS, which differs from the administered peptide by three residues (see, Figure 1), and the administered peptide in linear and cyclized form. Binding of antibodies MKD6 (anti-IAd), 10.2. 16
(anti-IAe7,s,k) and serum from mice treated and control mice was then tested. As can be seen in Figure 3, serum from treated mice contains high titers of antibodies that bind IAg7, but not IA\ Figure 4 shows the results of a similar experiment, with two additional controls and serum titered at different concentrations. The effects of boosting regimen and animal age on the ability to induce antibodies specific to I-A;~7 were also investigated. In these studies, groups of 10 mice at 3, 4, 5, and 6 weeks of age were injected with peptides as described above (initial dose =
50 or lOOμg/mouse), followed by boost of the indicated dose at 4 or 6 weeks. ELISA analysis as described for Figure 4 was then carried out. As shown in Figure 5, a specific immune response against the I-Ag7 peptide was boosted by administration of 100 μg/mouse at 4 weeks or 6 weeks, with slightly better results seen at 6 weeks. Figure 5 also shows the results of experiments designed to examine whether antibodies raised against I-Ag7 also recognize peptides in which the arginine at position 67 is changed to glutamine in accordance with the sequence of the corresponding region of IAS (see, Figure 1). As can be seen in Figure 5, this amino acid substitution was not recognized by the antibodies. Thus, the specificity of the immune response for I-Ag7 is apparently based on changes at other positions in these molecules.
Figure 6 shows the results of experiments designed to examine T cell mediation of the antibody responses. In these experiments, animals received in vivo treatment with either an Alum or PBS control or with 50, 100 or 200μg of the peptide of the invention, and were then sacrificed at either 4 or 6 weeks later. Reactivity of both splenic and lymph node-derived T cells to in vitro challenge with immunogens and mitogens was determined by measuring uptake of pH] thymidine according to standard techniques. As can be seen in Figure 6, there was a response to the mitogens ConA and LPS by T cells in 100% of the mice in every treatment, indicating that the peptide of the invention does not cause any general immune suppression. In vitro challenge with either the linear or cyclic I-Ag7 peptide induced a splenic response in treated mice; the percentage of mice showing a T cell response increased with the dosage of primary in vivo treatment, and control mice initially treated with Alum or PBS did not show this response. Additionally, challenge with peptides other than those of the invention (GAD peptide or mouse serum albumin (MSA)) did not induce T cell proliferation, indicating that T cells specifically reactive with these antigens were not present. T Cells reactive with linear or cyclic peptides of the invention were present in the spleen, but were not detected in the lymph nodes. These results indicate that circulating T cells specifically reactive with the peptides are present in animals which receive peptides of the invention. They also suggest that the antibody response detected above is T cell-mediated.
Example 3 This example described preparation of a cyclized peptides based on sequences from DQB1 *0302.
A. Synthesis and Characterization of Cyclic DQB1*0302 Peptide, Cyclized
Through Thioether Bond Formation
Peptide sequence: CH CONH-AAEY NSQKEVLERT AELDTVC-NH2 l s 1 1. Synthesis of peptide.
The linear peptide DQB 1 *302 was synthesized by Merrifield solid phase synthesis (SPPS) on an automated peptide synthesizer (433A, Applied Biosystems, Foster City, California. USA) as described generally by Luu et al. , Int. J. Peptide Protein Res. 47:91-96 (1996). The peptide was assembled from carboxy terminal end at 0.25 millimole scale on Rink amide MBHA resin (substitution level 0.49 mmoles per grain).
HOBt/HBTU coupling strategy was used for acylation of amines on the resin and piperidine was used for the deprotection of Fmoc protected α-amine of the amino acid on the resin. The side chain protection strategy is given in Table 2. N-methylpyrrolidinone (NMP) was used as a solvent for coupling/deprotection reactions and dichloromethane (DCM) was used for final washing of peptide resin. The deprotection was monitored by measuring the conductivity of Fmoc released.
Table 2. Side chain protection groups used in peptide synthesis.
Amino acid Side chain protection group
Asn(N), Cys(C), His(H), Gln(Q) Trt
Arg(R) Pbf
Lys(K) Boc Ser(S), Thr(T). Tyr(Y), Asp(D), Glu(E) t-Bu
Ala(A) and Leu(L) no protection group
After successful assembly of peptide chain on the resin, the peptide resin was dried in vacuum for 2 hours and subjected to bro oacetylation procedure. The resin was suspended in DMF containing 0. 1 % (by volume) DIEA and bromoacetic anhydride in 4: 1 molar excess was added. The suspension was mixed for 2 hours at room temperature. A small amount of slurry was taken and washed with DMF, methanol 3 times and finally with DCM. Then ninhydrine test was performed which was negative (no blue or puφle color). It indicated that the reaction was complete. The resin was then washed as described above and dried under vacuum.
After bromoacetylation, the peptide resin was dried in vacuum for two hours and subjected to peptide cleavage protocol. The resin was suspended in 10 ml of trifluoroacetic acid (TFA), 0.75 g of 4-(Methylmercapto)phenol and 0.75 ml of 4-Methoxybenzenethiol. The suspension was mixed for 2 hours at room temperature and then filtered into 1000 ml of pentane-acetone solution (4: 1 by volume). The clear solvent was removed by centrifugation. The precipitate (peptide) was washed with pentane-acetone solution three more times (50 ml each time) and finally with pentane (50 ml). The crude linear peptide was dried in vacuum for 1 hour. It was subjected to reverse phase analytical HPLC using C 18 column for quality control.
2. Cyclization of peptide by forming thioether bridge. For cyclization, the linear peptide was dissolved in argon sparged aqueous
0.1M sodium bicarbonate solution at concentration 1 mg/ml. Cyclization reaction was allowed to go overnight. The solution was centrifuged and the supernatant was checked by HPLC. The retention time for cyclic peptide was about 4 minutes less than for linear peptide. Peptide solution was Iyophilized and purified.
3. Peptide purification.
Peptide was purified on preparative reverse phase HPLC system applying gradient method. The solvents used were: 0. 1 % TFA in water and 0. 1 % TFA in acetonitrile. The fractions were checked on analytical HPLC. The pure fractions as indicated by HPLC were pooled and Iyophilized. Overall purity of peptide was over 78% .
4. Peptide characterization.
Peptide was characterized by the chromatogram from analytical HPLC and by mass-spectrometry. Molecular weight of cyclic peptide was 2564 amu.
B. Synthesis and Characterization of Cyclic DQB1*0302 Peptide, Cyclized
Through Disulfide Bond Formation.
Peptide sequence: CAAEYWNSQKEVLERTRAELDTVC-NH2 .
I s-s 1 1. Synthesis of peptide.
The linear peptide DQB] *302 was synthesized by Merrifield solid phase synthesis (SPPS) on an automated peptide synthesizer (433 A, Applied Biosystems, Foster
City, California, USA) as described generally by Luu et al. , Int. J. Peptide Protein Res.
47:91-96 (1996). The peptide was assembled from carboxy terminal end at 0.25 millimole scale on Rink amide MBHA resin (substitution level 0.49 mmoles per gram).
HOBt/HBTU coupling strategy was used for acylation of amines on the resin and piperidine was used for the deprotection of Fmoc protected α-amine of the amino acid on the resin. The side chain protection group is given in Table 3. N-methylpyrrolidinone (NMP) was used as a solvent for coupling/deprotection reactions and dichloromethane (DCM) was used for final washing of peptide resin. The deprotection was monitored by measuring the conductivity of Fmoc released.
Table 3. Side chain protection groups used in peptide synthesis.
Amino acid Side chain protection group
Asn(N), Cys(C), His(H), Gln(Q) Trt
Arg(R) Pbf
Lys(K) Boc Ser(S), Thr(T), Tyr(Y). Asp(D), Glu(E) t-Bu
Ala(A) and Leu(L) no protection group
After successful assembly of peptide chain on the resin, the peptide resin was dried in vacuum for 2 hours and subjected to peptide cleavage protocol. The resin was suspended in 10 ml of trifluoroacetic acid (TFA), 0.75g of 4-(Methyl- mercapto)phenol and 0.75 ml of 4-Methoxy-benzenethiol. The suspension was mixed for 2 hours at room temperature and then filtered into 1000 ml of pentane-acetone solution
(4: 1 by volume). The clear solvent was removed by centrifugation. The precipitate (peptide) was washed with pentane-acetone solution three more times (50 ml each time) and finally with pentane (50 ml). The crude linear peptide was dried in vacuum for 1 hour. It was subjected to reverse phase analytical HPLC using C18 column for quality control.
2. Cyclization of peptide through disulfide bond formation.
For cyclization peptide was dissolved in water at concentration 1 mg/ml, pH of the solution was brought to 8-9 by adding ammonium hydroxide. This solution was kept at 40°C for 3-4 hours so that peptide cyclized. After lyophilization peptide was checked by the same analytical HPLC. The retention time for cyclic peptide is about 4 minutes less than for linear peptide.
3. Peptide purification. Peptide was purified on preparative reverse phase HPLC system applying gradient method. The solvents used were: 0. 1 % TFA in water and 0. 1 % TFA in acetonitrile. The fractions were checked on analytical HPLC. The pure fractions as indicated by HPLC were pooled and Iyophilized. Overall purity of peptide was over 78%.
4. Peptide characterization.
Peptide was characterized by the chromatogram from analytical HPLC and by mass-spectrometry. Molecular weight of cyclic peptide was 2625 amu.
The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incoφorated by reference.
Claims (14)
1. A method of inducing an immune response against an HLA-DQ molecule in a patient, the method comprising administering to the patient an immunologically effective amount of a pharmaceutical composition comprising an adjuvant and a cyclic immunogenic MHC polypeptide from a hypervariable region of a HLA-DQ molecule.
2. The method of claim 1 , wherein the hypervariable region is in the β chain of the HLA-DQ molecule.
3. The method of claim 1 , wherein the cyclic immunogenic MHC polypeptide consists of about 20 to about 30 residues.
4. The method of claim 1 , wherein the immunogenic MHC polypeptide comprises amino acid residues 57-78 of a protein encoded by DQB 1*0302.
5. The method of claim 1 , wherein the immunogenic MHC polypeptide has the amino acid sequence CAAEYWNSQKEVLERTRAELDTVC.
6. The method of claim 1 , wherein the administration is parenteral.
7. The method of claim 1 , wherein the adjuvant is alum.
8. A method of treating or preventing insulin dependent diabetes mellitus in a patient, the method comprising administering to the patient an immunologically effective amount of a pharmaceutical composition comprising an adjuvant and a cyclic immunogenic MHC polypeptide from a hypervariable region of a HLA-DQ molecule.
9. The method of claim 8. wherein the hypervariable region is in the β chain of the HLA-DQ molecule.
10 The method of claim 8, wherein the cyclic immunogenic MHC polypeptide consists of about 20 to about 30 residues.
11. The method of claim 8, wherein the immunogenic MHC polypeptide comprises amino acid residues 57-78 of a protein encoded by DQB1 *0302.
12. The method of claim 8, wherein the immunogenic MHC polypeptide has the amino acid sequence CAAEYWNSQKEVLERTRAELDTVC.
13. The method of claim 8, wherein the administration is parenteral
14. The method of claim 8, wherein the adjuvant is alum
15 The method of claim 8, wherein the immunogenic MHC polypeptide is administered prophylactically
16 A pharmaceutical composition comprising an adjuvant and an isolated cyclic immunogenic MHC polypeptide trom a hypervariable region of a HLA-DQ molecule.
17 The composition of claim 16, wherein the hypervariable region is in the β chain of the HLA-DQ molecule.
18 The composition of claim 16, wherein the cyclic immunogenic MHC polypeptide consists of about 20 to about 30 residues
19 The composition of claim 16, wherein the immunogenic MHC polypeptide comprises amino acid residues 57-78 of a protein encoded by DQB1 *0302
20 The composition of claim 16, wherein the immunogenic MHC polypeptide has the amino acid sequence CAAEYWNSQKEVLERTRAELDTVC
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1479096P | 1996-04-03 | 1996-04-03 | |
US60/014790 | 1996-04-03 | ||
PCT/US1997/005461 WO1997036601A1 (en) | 1996-04-03 | 1997-04-02 | Cyclic peptide vaccines for treatment and prevention of diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2605097A true AU2605097A (en) | 1997-10-22 |
AU713067B2 AU713067B2 (en) | 1999-11-25 |
Family
ID=21767765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU26050/97A Ceased AU713067B2 (en) | 1996-04-03 | 1997-04-02 | Cyclic peptide vaccines for treatment and prevention of diabetes |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0954324A4 (en) |
JP (1) | JP2000509022A (en) |
AU (1) | AU713067B2 (en) |
CA (1) | CA2250814A1 (en) |
WO (1) | WO1997036601A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
JP2008523815A (en) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | Humanized amyloid beta antibody for use in improving cognition |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
EP2182983B1 (en) | 2007-07-27 | 2014-05-21 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases with humanised anti-abeta antibodies |
JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986007464A1 (en) * | 1985-06-14 | 1986-12-18 | Genetic Systems Corporation | Methods for identifying alleles associated with increased risk of diabetes |
CA1327162C (en) * | 1987-04-09 | 1994-02-22 | Board Of Trustees Of The Leland Stanford Junior University (The) | Method for prophylactically treating an individual for an autoimmune disease |
GB9201023D0 (en) * | 1992-01-17 | 1992-03-11 | Medical Res Council | Vaccines |
-
1997
- 1997-04-02 CA CA002250814A patent/CA2250814A1/en not_active Abandoned
- 1997-04-02 WO PCT/US1997/005461 patent/WO1997036601A1/en not_active Application Discontinuation
- 1997-04-02 EP EP97917819A patent/EP0954324A4/en not_active Withdrawn
- 1997-04-02 AU AU26050/97A patent/AU713067B2/en not_active Ceased
- 1997-04-02 JP JP9535577A patent/JP2000509022A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO1997036601A1 (en) | 1997-10-09 |
AU713067B2 (en) | 1999-11-25 |
EP0954324A1 (en) | 1999-11-10 |
EP0954324A4 (en) | 2000-11-02 |
CA2250814A1 (en) | 1997-10-09 |
JP2000509022A (en) | 2000-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6197926B1 (en) | Methods for treatment of diabetes using peptide analogues of insulin | |
US6077680A (en) | ShK toxin compositions and methods of use | |
JP2009213483A (en) | Soluble mhc complex and method of use thereof | |
AU713067B2 (en) | Cyclic peptide vaccines for treatment and prevention of diabetes | |
US20070129307A1 (en) | Insulin epitopes for the treatment of type 1 diabetes | |
US6171590B1 (en) | Chemokine receptor peptide for inducing an immune response | |
US7122193B1 (en) | Retro peptides, antibodies thereto and their uses for vaccination and in vitro diagnosis | |
EP0286447B1 (en) | Method and agents relating to prophylactic treatment of autoimmune diseases | |
US6045796A (en) | Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease | |
CA2152075C (en) | Vaccination with peptide of mhc class ii molecules for treatment of autoimmune disease | |
CN1082053A (en) | Synthetic polypeptide | |
US20060040863A1 (en) | Methods for treatment of diabetes using peptide analogues of insulin | |
EP1007547A1 (en) | Peptides comprising a t-cell epitope specific to collagen ii | |
AU775484C (en) | Peptide and peptide analogues for the treatment and prevention of diabetes | |
WO1996031617A1 (en) | Method of production of antigen-specific glycosylation inhibiting factor | |
Langton et al. | Structural features of an antigen required for cellular interactions and for T cell activation in a MHC-restricted response. | |
US20040180063A1 (en) | Vaccination with peptide of MHC class ll molecules for treatment of autoimmune disease | |
AU4863900A (en) | Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |